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Abstract
Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and cyclic
GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides, their
signalling pathways and, consequently, myriad biological responses in health and disease.
Currently, a small number of PDE inhibitors are used clinically for treating the pathophysiological
dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction,
pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic
obstructive pulmonary disease. However, pharmaceutical interest in PDEs has been reignited by
the increasing understanding of the roles of individual PDEs in regulating the subcellular
compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based
design of novel specific inhibitors and by the development of more sophisticated strategies to
target individual PDE variants.
Efficient integration of myriad extracellular and intracellular signals is required to maintain
adaptive cellular functioning. Dysregulation of this integration promotes maladaptive
cellular functions and underpins human diseases. Numerous distinct cellular signal
transduction systems have evolved to allow cells to receive these various inputs, to translate
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their codes and, subsequently, to transduce and integrate their meanings. Two of these, the
cAMP and the cGMP signalling systems (sometimes together referred to as the cyclic
nucleotide signalling system), are among the earliest identified signal transduction systems.
Advances in our understanding of the mechanisms by which cellular functions are altered
through cyclic nucleotide signalling are enabling the identification and development of
therapeutic agents for use in numerous human diseases.
The cAMP- and cGMP-signalling systems regulate a vast number of physiological
processes, including visual transduction, cell proliferation and differentiation, gene
expression, inflammation, apoptosis and metabolic pathways such as steroidogenesis, insulin
secretion and glycogen synthesis, as well as glycogenolysis, lipogenesis and lipolysis1–3.
Once synthesized by adenylyl cyclases or guanylyl cyclases, respectively, cAMP and cGMP
transduce signal-encoded information by acting through a number of cellular effectors.
These include cAMP- or cGMP-activated protein kinases (protein kinase A (PKA) or PKG,
respectively), cyclic nucleotide-gated ion channels, a family of two cAMP-activated guanine
nucleotide exchange proteins (exchange factors directly activated by cAMP 1 (EPAC1) and
EPAC2) and a limited group of enzymes from the cyclic nucleotide phosphodiesterase
(PDE) family, which contain allosteric cyclic nucleotide-binding sites in addition to their
catalytic sites1–3. Because the activities of several of these effectors can be altered
simultaneously in response to increases in cellular cAMP or cGMP, cyclic nucleotide-
elevating agents can trigger multiple cellular signalling events that — when integrated —
yield a series of finely-tuned ‘read-outs’ and that markedly affect the numerous cellular
functions listed above.
The functional impact and therapeutic utility of agents that increase the synthesis of either
cAMP or cGMP have been established4–7. Indeed, agents that are designed to act by binding
to and activating selected G protein-coupled receptors (GPCRs), including drugs such as
salmeterol (for asthma)7 or exendin-4 (for diabetes)8, affect cellular functions by stimulating
adenylyl cyclases. Similarly, agents that promote guanylyl cyclase-catalysed synthesis of
cGMP have therapeutic utility; these include nitric oxide donor drugs such as glyceryl
trinitrate (for angina therapy)9 or the natriuretic peptide-inspired drugs10 such as nesiritide, a
recombinant form of human B-type natriuretic peptide (BNP).
The functional impact and therapeutic utility of blocking cyclic nucleotide hydrolysis
catalysed by cyclic nucleotide PDEs have also long been recognized. Indeed, shortly after
discovering that cAMP was the heat-stable factor responsible for the activation of hepatic
glycogen phosphorylase by adrenaline, Sutherland and colleagues11 identified the enzymatic
activity of PDE as the cellular activity responsible for the hydrolysis of the 3′,5′
phosphodiester bond of cAMP to yield 5′-AMP, and they identified caffeine as an inhibitor
of this activity. Furthermore, caffeine, along with theophylline, was shown to potentiate the
cAMP-increasing effects of adrenaline as well as the ability of adrenaline to activate
phosphorylase or stimulate inotropic responses in perfused hearts12.
These early findings highlighted the importance of PDEs as essential regulators of
intracellular cyclic nucleotide concentrations and their biological effects. The subsequent
years have seen the confirmation of the crucial roles of PDEs as regulators of intracellular
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cyclic nucleotide concentrations, as well as the discovery of a host of biological processes
involving these second messengers in health and disease1–3. For these reasons, and others
detailed in this Review, PDEs have consistently been considered to be key therapeutic
targets, from both clinical and economic perspectives.
Nevertheless, at present only a few PDE inhibitors are in widespread clinical use. However,
recent advances have renewed enthusiasm for further investigating their therapeutic
potential. First, individual PDEs have been shown to control select cyclic nucleotide-
regulated events by their integration into specific multi-molecular regulatory signalling
complexes, termed ‘signalosomes’, and through their regulation of cAMP or cGMP levels
within distinct and largely non-overlapping intracellular cyclic nucleotide
compartments13,14. Indeed, there is evidence to suggest that the disruption of these
signalling modules and the resultant dysregulation of this compartment-specific signalling
via genetic, epigenetic or cellular environmental influences may be associated with many
disease states, including asthma, inflammation, erectile dysfunction, hypertension, heart
failure and cardiac arrhythmias1–3,13,14.
Furthermore, it has been suggested that targeting these compartments could yield greater
therapeutic specificity. There is growing confidence that this will be possible, given the
recent remarkable advances in PDE biology and structural biology, including structure–
function studies, advanced proteomics, X-ray crystallographic analysis of PDEs15 and PDE–
inhibitor complexes16,17, as well as the development of more sophisticated strategies to
examine the unique allosteric interactions between the catalytic and regulatory domains of
PDEs18 and to target specific PDEs in complex with their signalosome partners19. These
advances may enable the development of effective therapies for a broad range of clinical
applications, including asthma, inflammation, depression, stroke, schizophrenia, chronic
cardiac failure and atherosclerosis. This Review focuses on these recent advances, as well as
on translational research in the PDE field.
History of PDEs as therapeutic targets
Xanthine derivatives, including theophylline and caffeine, were clinically used as
bronchodilators (for the treatment of asthma), diuretics and inotropic agents before they
were identified as non-selective PDE inhibitors20,21. However, their unfavourable risk–
benefit ratio and side-effect profiles considerably impeded their therapeutic success. In the
1970s and 1980s, simple gel filtration and ion exchange chromatography of tissue extracts
revealed multiple peaks of PDE activities, with each peak exhibiting different specificities
and affinities for cGMP and/or cAMP as well as different sensitivities to available
pharmacological agents and effectors such as calcium/calmodulin (the calcium/calmodulin-
sensitive PDE is now known as PDE1)22–26. Consequently, drugs were successfully utilized
to subdivide cAMP-hydrolysing PDEs into cilostamide-sensitive (now known as PDE3) and
Ro20-1724-sensitive (now known as PDE4) enzymes27. Responsiveness to cGMP was also
used to identify distinct PDEs: that is, cGMP-inhibited cAMP-hydrolysing PDEs (now
known as PDE3)25, cGMP-stimulated cAMP-hydrolysing PDEs (now known as PDE2)27
and cGMP-specific PDEs (now known as PDE5)26.
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Thus, molecular diversity among PDEs was recognized long before modern molecular
biology and molecular genetics revealed the large number and complexity of PDEs, and
before the current organization of the large mammalian PDE superfamily into 11 structurally
related but functionally distinct PDE gene families (PDE1 to PDE11)1–3 (FIG. 1). The
recognition that the molecular diversity of PDEs is coupled to the regulation of specific and
functionally important physiological and pathophysiological processes (TABLES 1,2) has
spurred the pharmaceutical industry to develop specific second-generation inhibitors that are
selective for 9 of the 11 PDE families (TABLE 2).
In the 1980s, PDE3 and PDE4 were the primary therapeutic targets. As PDE3 inhibitors
were discovered to exhibit cardiotonic, inotropic, bronchodilatory and vasodilatory activities
in several species, they were developed as cardiotonic agents to replace or add to cardiac
glycosides in the treatment of cardiac failure20,28. PDE4 inhibitors have antidepressive and
anti-inflammatory activities, but were initially developed to treat chronic obstructive
pulmonary disease (COPD) and asthma20,29,30. Unfortunately, the hopes that arose from
preclinical studies were not completely realized in clinical trials, and many of these early
second-generation PDE3 and PDE4 inhibitors were not approved owing to lack of efficacy
and the presence of intolerable side effects20,28,31.
As discussed below and listed in TABLE 2, other second-generation inhibitors of PDE3 and
PDE4, with more favourable risk–benefit profiles, are now available20,30–32 and hold
promise for use in additional disease states. During early unsuccessful clinical trials
assessing the potential of the PDE5 inhibitor sildenafil (Viagra; Pfizer) in the treatment of
angina and coronary artery disease, responses in off-target tissues dramatically changed the
focus of this agent to erectile dysfunction. The enormous success of PDE5 inhibitors in
treating erectile dysfunction33 and, more recently, pulmonary hypertension34 has been a
major contributing factor in maintaining and expanding pharmaceutical interest in PDEs as
promising therapeutic targets for many diseases (TABLE 2).
Overview of the PDEs
Structural organization
The 11 structurally related but functionally distinct gene families (PDE1 to PDE11) that
comprise the PDE superfamily differ in their cellular functions, primary structures, affinities
for cAMP and cGMP, catalytic properties and responses to specific activators, inhibitors and
effectors, as well as in their mechanisms of regulation1–3 (FIG. 1; TABLES 1,2). Most
families contain several PDE genes (for example, PDE1A, PDE1B and PDE1C (FIG. 1;
TABLE 1)), which together generate close to 100 PDE isozymes by alternative mRNA
splicing or transcriptional processing.
As modular proteins, PDEs exhibit a common structural organization, with divergent amino-
terminal regulatory regions (FIG. 1) and a conserved carboxy-terminal catalytic core. Some
PDEs specifically hydrolyse cAMP (PDE4, PDE7 and PDE8), whereas others specifically
hydrolyse cGMP (PDE5, PDE6 and PDE9), and some hydrolyse both (PDE1, PDE2, PDE3,
PDE10 and PDE11)1–3. The N-terminal regulatory regions of PDEs contain structural
determinants that target individual PDEs to different sub-cellular locations and
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signalosomes13,14,19, and also allow individual PDEs to specifically respond to different
post-translational modifications, regulatory molecules and signals. These structural elements
include dimerization domains, autoinhibitory modules, binding sites for ligands and
allosteric effectors, phosphorylation sites and other covalent modification sites, domains for
isoform-specific protein–protein interactions with specific scaffolds and regulatory partners,
and so on (FIG. 1).
Most cells contain representatives of more than one PDE family, but in varying amounts,
proportions and subcellular locations. Although PDEs exhibit a broad tissue distribution
(TABLE 1), some cells are relatively enriched in specific PDEs; for example, the
photoreceptor PDE6 is almost exclusively expressed in retinal rods and cones3.
Architecture of the catalytic core of PDEs: implications for the design of inhibitors
X-ray crystal structures of isolated catalytic domains of nine PDE families (PDE1–PDE5
and PDE7–PDE10)15, of the near-full-length PDE2A18 and of PDE4 catalytic domains with
a fragment of upstream conserved regions (UCRs)35 have demonstrated that the catalytic
domains of PDEs share a similar topography, composed of ~350 amino acids folded into 16
helices. Across the PDE families, the active site forms a deep hydrophobic pocket that
contains a PDE-specific, histidine-containing signature motif, HD(X2) H(X4)N, and binding
sites for two divalent metal ions that are essential for catalytic function36. Of the six
invariant residues in the metal binding site, one (His160 in PDE4D2) has been proposed to
serve as a general acid for catalysis15,37. The catalytic pocket is lined with highly conserved
and invariant residues, including an invariant glutamine (Gln369 in PDE4D2, Gln453 in
PDE9A2 and Gln726 in PDE10A2) that forms crucial hydrogen bonds with substrates (FIG.
2a,b) and inhibitors15,16,38,39 (FIG. 2c,d) (see also Supplementary information S1 (figure),
part A; Supplementary information S2 (figure)).
Analyses of crystal structures of PDE–inhibitor complexes (FIG. 2c,d) (see also
Supplementary information S1 (figure), part A; Supplementary information S2 (figure))
suggest that two conserved residues, the invariant glutamine and a highly conserved
phenylalanine (Phe372 in PDE4D2; Trp621 in PDE11A2), are essential for inhibitor
binding15,16,36,40. The formation of hydrogen bonds with the invariant glutamine determines
the orientation of inhibitors, and conserved hydrophobic residues (Ile336 and Phe340 in
PDE4D2)16,40 form a ‘hydrophobic clamp’ that anchors inhibitors in the pocket and wedges
their ring structures against Phe372 in PDE4D2 (Supplementary information S1 (figure),
part A)16,36,38,40 and against Phe456 and Phe729 in PDE9A and PDE10A, respectively
(Supplementary information S2 (figure))16,17,41–45.
In addition to conserved elements that are responsible for binding to cyclic nucleotides and
inhibitors, the catalytic core contains variable determinants that regulate PDE family-
specific substrate and inhibitor affinities and selectivities3,17,46 (TABLE 2). Inhibitor
selectivity for individual PDE families is regulated by these variable active site residues,
which define not only the chemical nature of the interactions but also the slightly different
sizes of the subpockets38,45,47. For example, the formation of a hydrogen bond between
inhibitors and the variable Tyr424 residue of PDE9A, which is replaced by phenylalanine in
other PDE families (except for PDE8), substantially improved the affinity and selectivity of
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PDE9 inhibitors43,44 (Supplementary information S2 (figure), parts A and B). In addition,
most PDE families — that is, PDE1 to PDE4 and PDE7 to PDE10 — have relatively rigid
pockets at the active sites, further constraining inhibitor structure with implications
regarding binding specificity and family selectivity. This rigidity was demonstrated by the
co-crystallization of two enantiomers of Merck’s inhibitors L-869298 and L-869299 with
PDE4D (Supplementary information S1 (figure), part B)48. L-869299 inhibits PDE4D 107-
fold more weakly than L-869298 (with a half-maximal inhibitory concentration (IC50) of 43
nM versus 0.4 nM). As both enantiomers assumed similar conformations or orientations
owing to the rigidity of the PDE4D catalytic pocket, this suggested that L-869299 was
forced to bind in an unfavourable orientation (Supplementary information S1 (figure), part
B).
The catalytic domain of PDE5, however, appears to be unique for its ability to adopt
multiple conformations of its helical H-loop (residues 660–683) and M-loop (residues 788–
811) at the active site, upon binding to different inhibitors, including isobutyl-1-
methylxanthine (IBMX), sildenafil and vardenafil (Levitra; Bayer) (Supplementary
information S1 (figure), parts C and D). Crystal structures showed that both the H- and M-
loops of PDE5 exhibit different conformations when sildenafil and vardenafil bind, which
may account for the values and is prob-5–20-fold differences in their IC50 ably related to
their somewhat distinct core structures (Supplementary information S1 (figure), part D)49,50.
Although many of the family-selective inhibitors listed in TABLE 2 have been developed
using classical medicinal chemistry approaches, a structure-based design approach is now
the preferred path for generating novel inhibitors (BOX 1). Family-selective PDE inhibitors
(TABLE 2) have served as essential basic research tools to help understand both the
complexities of cyclic nucleotide signalling pathways and the different regulatory and
functional roles of individual PDEs in intact cells (TABLE 2). Family-selective PDE
inhibitors are also potential therapeutics for a broad range of diseases, with greater
specificity and fewer side effects than the non-selective first-generation PDE inhibitors such
as theophylline, caffeine and other xanthine derivatives (FIG. 1; TABLE 2).
Box 1
Structure-based design of PDE inhibitors
Many of the high-affinity, family-selective, competitive inhibitors listed in TABLE 2
were generated using classical medicinal chemistry approaches16,17. This strategy, which
almost exclusively identified compounds that competed with the binding of cyclic
nucleotide substrates at the catalytic sites of phosphodiesterases (PDEs), involved
screening extensive molecular libraries to identify lead compounds with modest potency
and selectivity. These lead compounds served as scaffolds for systematic derivatization
and chemical modification or optimization to produce second-generation, family-
selective, competitive inhibitors with desired affinities, selectivities, potencies and
favourable pharmacokinetics and safety profiles.
More recently, however, information from crystal structures of the catalytic sites of PDEs
and of PDE–inhibitor complexes is driving the design of new inhibitors15,16,17,40,163.
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Lead candidates (usually of low affinity) are identified by a combination of compound
library screening and high-throughput co-crystallization of PDE–inhibitor complexes.
More potent and selective inhibitors are then generated by an iterative process of co-
crystallography, whereby compounds are identified by additional focused library
screening and/or they are chemically synthesized after structure-informed virtual
screening and computational design. This approach has resulted in the discovery of
several novel pyrazole derivatives as potent and selective PDE4 inhibitors40,163, of
pyrazolopyrimidinones (such as PF-04447943) as PDE9A inhibitors for cognitive
disorders43,44, and of pyridopyrazo-loquinolines (such as PF-2545920) as PDE10A
inhibitors for the treatment of schizophrenia41,42,45. In the latter case, the co-
crystallization of lead scaffold triarylimidazole compounds (identified by high-
throughput screening of the Pfizer compound library) with the catalytic fragment of
PDE10A identified a unique, PDE10A-specific, hydrophobic selectivity pocket for
PDE10A inhibitors. This structural information was crucial in the design and chemical
synthesis of PF-2545920, a potent (with a half-maximal inhibitory concentration (IC50)
of 0.37 nM) and highly selective PDE10A inhibitor45.
Compartmentalization and the signalosome concept
Early studies, particularly those reporting data that were consistent with the novel idea that
cellular cAMP signalling was compartmentalized51,52, were met with considerable
resistance. Indeed, it was not until the purification of A-kinase anchor proteins (AKAPs) and
their identification as selective subcellular PKA tethers53,54 that a potential mechanism for
compartmentalized cAMP signalling was conceived. More recently, the use of several
distinct types of cAMP biosensors, including those that utilize fluorescence resonance
energy transfer (FRET), in combination with biochemical approaches, has confirmed that
cells regulate their intracellular levels of cAMP or cGMP in a highly compartmentalized
manner and generate functionally separate intracellular cyclic nucleotide pools55–60.
Briefly, compartmentalized cyclic nucleotide signalling is established via the formation of
cyclic nucleotide signalosomes, in which unique combinations of cyclic nucleotide effectors
(PKAs, EPACs, cyclic nucleotide-gated ion channels or PKGs) and individual — or subsets
of — PDEs form specific complexes via protein–protein interactions with one another
and/or with localized scaffolding proteins, such as AKAPs, β-arrestin or receptor of
activated protein kinase C1 (RACK1)13,14,61. Different AKAPs, for example, serve dual
functions as tethers for PKA at different subcellular locations in close proximity to PKA
substrates in order to promote selective phosphorylation, and as scaffolds for signalosomes
with different proportions of PKA, adenylyl cyclases, other kinases, phosphatases, EPACs,
PDEs and other effector molecules13,14,61. Thus, as components of specific signalosomes,
PDEs modulate the diffusion and turnover of cyclic nucleotide gradients within spatially
restricted and temporally regulated compartments, and they reduce the diffusion of cyclic
nucleotide signals into neighbouring compartments. TABLE 3 and Supplementary
information S3 (table) provide a comprehensive list of specific PDE-containing
signalosomes, and include the specific PDE isoform and its signalling or interacting partners
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(both inferred and identified), the subcellular compartment or ‘address’ of the signalosome
and the signalling pathway or cellular function regulated by the specific signalosome.
The integration of individual PDEs into specific signalosomes within different functional
compartments has dramatically delineated the functional roles of individual PDEs and
clearly linked the large number of PDE isoforms to the compartmentalized regulation of
specific cyclic nucleotide signalling pathways and biological responses (TABLES 1,3). For
example, PDE4B, PDE4D and PDE3A — as components of different, specifically localized,
AKAP-based signalosomes in rodent cardiomyocytes — may regulate cAMP signalling
within distinct cellular domains that regulate largely non-overlapping functions related to
myocardial contractility (BOX 2; FIG. 3). From a teleological perspective, the large number
of known PDE isoforms readily meets the demands of the compartmentalized regulation of
individual cyclic nucleotide signalling pathways, with its inherent requirement to tether or
target different PDEs to specific signalosomes at many different intracellular locations55–60.
The incorporation of different types of PDEs into specific signalosomes (that is, PDEs from
different PDE families and subfamilies or from different splice, transcriptional or
translational variants, and so on), with their distinct intrinsic characteristics and regulatory
properties, contributes to both the fine-tuning and specificity of compartmentalized cyclic
nucleotide signalling1–3,13,14. In addition, different PDE isoforms can integrate multiple
distinct cellular inputs and allow crosstalk between cyclic nucleotides and other signalling
networks and systems13,14,58,59,61–64.
Box 2
Signalosome coupling of cAMP–PKA signalling to myocardial contractility
In the rodent heart, activation of β-adrenergic receptors increases myocardial contractility
by coupling cAMP–protein kinase A (PKA) signalling to intracellular calcium
cycling166. PKA-induced phosphorylation of L-type calcium channels in T-tubules and of
ryanodine-sensitive calcium channels (also known as ryanodine receptor 2 (RYR2)) in
the sarcoplasmic reticulum (SR) increase calcium influx and calcium-induced calcium
release from the SR during systole, respectively. Phosphorylation of phospholamban
(PLB) blocks its inhibitory interactions with sarcoplasmic/endoplasmic reticulum
calcium ATPase 2 (SERCA2), the calcium-transporting ATPase of the SR, and results in
increased calcium accumulation in the SR during diastole166 (FIG. 3). These actions
increase the amplitude of myocardial calcium transients, resulting in enhanced inotropic
and lusitropic responses.
As components of different A-kinase anchor protein (AKAP)-based signalosomes,
phosphodiesterase 4B (PDE4B), PDE4D and PDE3A each regulate different phases of
the calcium-mediated excitation–contraction coupling cycle166. AKAP15/AKAP18 is
important in the targeting and tethering of PKA and PDE4B to L-type calcium channels;
AKAP6 (also known as mAKAP) in the targeting and tethering of PDE4D to RYR2; and
AKAP18δ in the targeting and tethering of PDE3A to SERCA2–PLB regulatory
complexes (known as signalosomes)167–169. In this manner, PDE4B regulates cAMP–
PKA-stimulated calcium influx, PDE4D regulates calcium-induced calcium release from
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the SR, and PDE3A regulates increased accumulation of calcium in the SR167–169. A
PDE4D variant has also been reported to associate with SERCA2 in the rodent heart170.
Studies in Pde4b- and Pde4d-knockout mice strongly suggest that compartmentalized
PDE4B and PDE4D are crucial for maintaining the physiological equilibrium between
PKA-induced channel phosphorylation and excitation–contraction coupling, as
hyperphosphorylation of L-type calcium channels and RYR2 channel proteins in Pde4b-
and Pde4d-knockout mice (owing to increased cAMP–PKA signalling), respectively,
leads to alterations in intracellular calcium cycling, ventricular arrhythmias and cardiac
dysfunction167–169. In the rodent heart, a macromolecular complex containing the
phosphoinositide 3-kinase γ-subunit (PI3Kγ), PDE3A, PDE4A and PDE4B was recently
proposed to have a protective role against ventricular arrhythmias by regulating the
phosphorylation of L-type calcium channels and PLB171. Although PDE4 protects
against cAMP–PKA-induced arrhythmias in isolated human atrial myocytes172, the role
of PDE4 isoforms in human cardiac function is uncertain, as there are potential
cardiovascular risks that might accompany the chronic usage of drugs such as roflumilast
(approved for the treatment of chronic obstructive pulmonary disease), which inhibit all
PDE4 isoforms. A recent report has identified a crucial role for PDE3, but not PDE4, in
regulating β1- and β2-adrenergic receptor-mediated effects on myocardial contractility in
the hearts of patients with heart failure173.
Although this substantial expansion in knowledge has revealed many new therapeutic
opportunities, it has also raised additional questions and challenges regarding the
development of specific therapeutics and the design of novel targeting strategies. Advances
in the identification of protein components of signalosomes, in the biochemical
understanding of protein–protein interactions and in the structural insights provided by X-
ray crystallographic analyses of PDE catalytic cores and PDE–inhibitor co-crystal
complexes, as well as more complex structures, are allowing optimization of the structure-
based design of competitive inhibitors that are selective for particular PDE families and
subfamilies (BOX 1; TABLE 2). These advances are also beginning to permit the targeting
of intramolecular interactions between the regulatory and catalytic regions of PDE
molecules18,35, as well as the targeting of intermolecular protein–protein interactions
between PDEs and their regulatory partners13,14,19,58,59,61–65. There is hope and confidence
that this emerging confluence between PDE biology and structure-based drug design,
together with the development of more sophisticated strategies to target specific PDEs in
complex with their signalosome partners, will hasten the development of third-generation
allosteric modulators and signalosome disruptors targeting individual PDEs that could be
used to treat a broad range of diseases.
Biological and pathological roles of PDEs
Family-selective PDE inhibitors have been valuable in delineating the specific signalling
pathways and cellular functions that are regulated by specific PDEs in animals and isolated
cells1–3 (TABLE 2). However, the inability of most available agents to distinguish between
the large numbers of family-specific isoforms expressed in most cells limits their value as
probes to some extent. More compelling are studies of PDE-knockout mice, studies in which
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specific PDEs have been knocked down with small interfering RNA (siRNA) or studies
highlighting the association of different PDE mutations with specific human diseases.
Indeed, data from these studies clearly demonstrate that the regulation of many cAMP- and
cGMP-signalling pathways by specific PDEs is non-redundant, genetically determined and
likely to be highly targetable (TABLES 1,2). For example, conclusive evidence that PDE3A
is crucial for oocyte maturation was obtained when it was found that female Pde3a-
knockout mice are sterile, most probably because PDE3A in oocytes regulates a specific
cAMP pool that controls the activation of maturation-promoting factor (which is formed
from the gene products of cyclin-dependent kinase 1 (CDK1) and cyclin B1 (CCNB1))66,67.
Thus, Pde3a-knockout mice provide proof of principle that oocyte PDE3A could be a
valuable contraceptive target; this hypothesis is supported by the fact that PDE3-selective
inhibitors prevent pregnancy in rodents and block the maturation of cultured oocytes in
many species, including rodents and humans66,67. Results from similar experimental
approaches have described numerous physiological and pathological roles of PDEs, as
discussed below and in TABLES 1–3, and have thus encouraged the design and testing of
new family-selective PDE inhibitors for use in numerous indications (TABLES 2,4).
Several human diseases are associated with mutations in genes encoding individual PDEs, or
with mutations in genes encoding proteins that are involved in the expression or function of
these PDEs (TABLE 1). For example, mutations in PDE6A and PDE6B are associated with
autosomal recessive retinitis pigmentosa68,69, whereas mutations in AILP1 (the gene
encoding aryl hydrocarbon receptor-interacting protein-like 1), a chaperone of PDE6A,
allow proteolytic destruction of PDE6A and are likely to cause Leber congenital amaurosis
type 4, a severe form of childhood blindness70. Partly because excess cGMP accumulation is
associated with retinal degeneration in model systems71, the use of certain PDE5 inhibitors
(for example, sildenafil and vardenafil) is contraindicated in patients with retinal
degeneration72. Similarly, human PDE4D haplotypes and single-nucleotide polymorphisms
(SNPs) have been correlated with ischaemic stroke73 and with responses to short-acting
bronchodilators in paediatric asthma74, whereas PDE4B SNPs correlate with
schizophrenia75. PDE8B expression regulates cAMP-mediated steroidogenesis76,77, and
PDE8B mutations are associated with isolated adrenal micronodular hyperplasia and other
human adrenal adenomas78,79. Inactivating PDE11A mutations were described in a
subgroup of patients with Cushing syndrome and bilateral micronodular adrenal
hyperplasia80. Also, certain PDE11 mutations may increase susceptibility to prostate
cancer81 or to adrenal and testicular tumours in patients with Carney complex82, a disease
that may be associated with inactivating mutations in the cAMP-dependent protein kinase
type 1 alpha regulatory subunit (PRKAR1A) gene.
Alterations in cyclic nucleotide signalling pathways also affect neoplastic cellular
transformation, tumour cell growth, progression and metastasis, as well as tumour cell
function83,84. Numerous PDE1- to PDE5-selective inhibitors, as well as PDE7-selective
inhibitors, have been reported to inhibit growth and induce apoptosis in many different
human cancer cell lines, which suggests a potential role for these drugs as antineoplastic
agents (TABLES 1,2). For example, elevated PDE7B expression is associated with poor
prognosis in chronic lymphocytic leukaemia (CLL), and selective PDE7 inhibitors
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(BRL-50481 and IR-202) increase cAMP–PKA signalling and apoptosis in CLL cells85.
These data identify PDE7B as both a biomarker and a target for treating CLL. Similarly,
inhibition of PDE4 activity or knockdown of PDE4D expression in malignant cells with
elevated PDE4 activities caused growth inhibition and apoptotic cell death in the malignant
cells, but not in the non-malignant cells86,87. Re-expression of PDE4D inhibited cell death,
which suggests that PDE4D might be both a tumour promoter and a therapeutic target in
certain cancers. These beneficial effects of reducing PDE-mediated cAMP hydrolysis
should, however, be tempered, given that cAMP can promote the growth of certain
carcinomas and that apparently inactivating mutations in some PDEs (for example, PDE8
and PDE11) can predispose to endocrine tumours88,89. The effects of PDE inhibitors on the
permeability of the blood–brain barrier may also alter the effects of other therapeutic
agents90.
cAMP and cGMP signalling pathways are important in cognition as well as in behavioural
function and dysfunction (TABLES 1,2). Results of recent studies confirm that certain PDEs
may be targets for ameliorating cognitive or behavioural deficits. Indeed, the PDE4 inhibitor
rolipram, which was initially developed as an antidepressant91, improves cognition and
long-term memory in rodents35,92,93. At a molecular level, the observation that Pde4d-
knockout mice exhibit antidepressive behaviour and show reduced antidepressant responses
to rolipram but not to other antidepressant drugs supports a role for PDE4D in cognition,
memory and antidepressive behaviour, whereas Pde4b-null preclinical models implicate this
enzyme in anxiety-related behaviour35,92,93. Mutations in DISC1 (disrupted in schizophrenia
homolog 1) and polymorphisms in PDE4B are both associated with schizophrenia75, and
DISC1 and PDE4B interact physically in cells to influence the catalytic activity of
PDE4B94,95; together, these observations support the notion that PDE4B is involved in
schizophrenia. In preclinical rodent models, highly selective PDE10A inhibitors elicited
anti-psychotic and pro-cognitive responses, and also increased sociality41,42,93 (TABLE 2).
Also, inhibition of PDE4 or PDE10A alleviated motor and behavioural deficits in a
transgenic R6/2 mouse model of Huntington’s disease, in which alterations in striatal
PDE10A preceded the motor symptoms of the disease96,97. These studies have increased
interest in developing PDE inhibitors as therapeutics for basal ganglia disorders.
PDE inhibitors in the clinic
Although many high-affinity, PDE-family-selective, competitive inhibitors have been
generated, only a limited number of second-generation agents have received regulatory
approval for widespread clinical use. Below, we describe some of the agents that are in
widespread use and those that may soon gain regulatory approval. A more comprehensive
list of the agents that are currently under development and in clinical trials is provided in
TABLE 2 and TABLE 4.
PDE3 inhibitors
Although PDE3 inhibitors produce acute inotropic, lusitropic and vasodilatory
haemodynamic responses in patients with heart failure25,28,98, chronic administration of the
PDE3 inhibitor milrinone (Primacor; Astellas Pharma/Sanofi) in such patients increased
annual mortality, most probably owing to arrhythmias and cardiac arrest98,99. Milrinone is
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approved, however, for the acute treatment of adults with decompensated and refractory
heart failure, and those awaiting heart transplants98. Another PDE3 inhibitor, cilostazol
(Pletal; Otsuka Pharmaceutical), is approved and widely used to treat intermittent
claudication, a relatively common lower-extremity peripheral arterial disease that is
characterized by ischaemia-induced leg pain or cramping100,101. Cilostazol increases
walking distance and reduces the clinical symptoms of intermittent claudication by cAMP-
mediated vasodilation and the inhibition of platelet activation and vascular wall
inflammation100,101.
PDE4 inhibitors
PDE4 isoforms have a relatively high level of expression in cells that regulate
immunoinflammatory responses and tissue remodelling29. Because early PDE4-selective
inhibitors — especially rolipram — exhibited potent cAMP-mediated anti-inflammatory
responses in various cellular and animal models, pharmaceutical companies invested heavily
in developing PDE4 inhibitors for clinically important, inflammation-related pulmonary
diseases, including COPD, asthma, allergic rhinitis and idiopathic pulmonary fibrosis29–31.
COPD is a major public health concern and a leading cause of death in societies where
smoking is prevalent. Clinically, COPD is characterized by progressive airway inflammation
and obstruction, as well as a decline in lung function, with acute recurrences and
exacerbations that lead to a markedly reduced quality of life and eventual death. Although
the development of rolipram and other PDE4 inhibitors was hampered owing to their
gastrointestinal side effects, especially nausea, emesis and diarrhoea, the potential of the
target encouraged further industry investment and led to the development of more advanced
PDE4 inhibitors. Two inhibitors, cilomilast and roflumilast, reached Phase III trials29–31;
roflumilast (Daliresp/Daxas; Takeda/Nycomed) is now approved as an oral treatment for
reducing the risk of exacerbations in patients with COPD who also have chronic
bronchitis29–32 (TABLES 2,4).
PDE5 inhibitors
Male erectile dysfunction is a widespread and distressing condition and is often associated
with significant co-morbidities, including hypertension, hyperlipidaemia, atherosclerosis and
diabetes33. As cGMP is a crucial physiological regulator of the nitric oxide-induced
vasodilation (which leads to penile erection) that occurs upon sexual stimulation, and given
that PDE5 has a relatively high expression in the corpus cavernosum, PDE5 inhibitors can
be used to prevent the destruction of cGMP and thereby enhance erectile function in
unaffected men or in patients with erectile dysfunction (secondary to deficiencies in nitric
oxide–cGMP signalling)33. Orally administered PDE5 inhibitors, the first being sildenafil,
followed by vardenafil and tadalafil (Cialis; Eli Lilly), have been highly successful in
treating erectile dysfunction. Avanafil (Stendra; Vivus), a rapidly acting PDE5-selective
inhibitor, has also been approved for the treatment of erectile dysfunction (TABLES 2,4).
Pulmonary arterial hypertension is characterized by increased mean pulmonary artery
pressure and increased pulmonary vascular resistance resulting from vasoconstriction and
hypertrophic structural remodelling of the small pulmonary arteries, which leads to
decreased oxygenation of blood, dyspnoea, decreased exercise capacity, reduced quality of
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life, heart failure and, eventually, death34,102,103. PDE5, which has a relatively high
expression in the airway and vascular smooth muscle, is thought to be a key regulator of
pulmonary vascular dilation and remodelling via its modulation of cGMP–PKG signalling.
PDE5 inhibitors such as sildenafil (marketed as Revatio by Pfizer), tadalafil (marketed as
Adcirca by Eli Lilly) and vardenafil are currently approved for the treatment of pulmonary
arterial hypertension34,102,103.
Today, xanthine derivatives (for example, theophylline and caffeine), which inhibit almost
all PDE families (except for PDE8 and PDE9), are clinically used primarily as
bronchodilators in the treatment of pulmonary diseases such as asthma, chronic bronchitis,
emphysema and COPD20,21. Another xanthine derivative, pentoxifylline (Trental; Sanofi) is
used to treat intermittent claudication secondary to chronic occlusive arterial disease. These
drugs, however, exhibit a narrow therapeutic window, and toxicity (nausea, emesis and
arrhythmias) is a major concern20. Theophylline is also currently being considered as an
important add-on therapy in cortico-steroid-resistant asthma and COPD21
(ClinicalTrials.gov identifier: NTC00241631). Dipyridamole, another non-selective PDE
inhibitor, inhibits platelet aggregation and is used to prevent post-surgical thromboembolic
events and stroke104.
Limitations of existing agents
Despite the therapeutic success of several PDE3, PDE4 and PDE5 inhibitors, off-target
effects limit their use. Although these inhibitors predominantly inhibit specific PDE families
and not virtually all PDEs, as is the case with methylxanthines, they unfortunately inhibit all
family members, even those in off-target locations, which produces undesirable effects. The
importance of understanding these off-target effects is increasingly being realized, as they
can both positively and negatively influence the risk–benefit profile of PDE inhibitors. For
example, in the case of the PDE3 inhibitor milrinone, it is not known whether its
cardiotoxicity is related to its inhibition of both PDE3A and PDE3B, its inhibition of
different pools of cardiac PDE3A that differentially regulate contractility and apoptosis, its
inhibition of other PDE families or to its interactions with non-PDE proteins98. Similarly,
the PDE4 inhibitors rolipram and cilomilast failed in clinical trials because of the dose-
limiting nausea- and emesis-associated off-target effects caused by the inhibition of PDE4
isoforms, possibly PDE4D, in the emetic centre in the brain20,31.
Conversely, some off-target effects of family-selective PDE inhibitors can positively affect
their efficacy and/or their safety profile. For example, it has been suggested that sildenafil-
induced inhibition of PDE1 may be responsible for some of the beneficial effects of this
PDE5 inhibitor in treating heart failure98,102. Indeed, PDE1 is more highly expressed than
PDE5 in the human myocardium, and inhibition of PDE1 in preclinical models of heart
failure blocks pathological vascular remodelling and cardiac hypertrophy105,106. Should the
unexpected protective effects of sildenafil in the heart be related to PDE1 inhibition, these
data would support the notion that dual PDE1 and PDE5 inhibition might be beneficial in
treating human cardiovascular diseases. Similarly, the ability of cilostazol to block
adenosine uptake into the myocardium (via mechanisms other than the inhibition of PDE3)
may be related to the reduced cardiotoxicity observed during chronic administration of
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cilostazol as compared to that observed following the chronic administration of
milrinone99–101,107.
The use of PDE family-selective inhibitors can also be limited by their direct or indirect
inhibition of other PDE family enzymes and/or their interaction with non-PDE proteins to
cause unacceptable toxicity, as well as by the roles of multiple PDE families in regulating
signalling pathways. As for interacting with non-PDE proteins, the PDE5 inhibitor
vardenafil has been reported to block calcium channels in rabbit pulmonary arteries and
human platelets108, and sildenafil has been reported to interact with multidrug resistance
protein 1 (MDR1; also known as ABCB1) and antigen peptide transporter 1 (APT1; also
known as ABCB2) to block drug extrusion from cells109. This latter off-target effect could
be potentially quite important in serving to reduce ABCB1- and ABCB2-mediated drug
resistance and thus improve the efficacy of some chemotherapeutic agents, perhaps
independently of PDE5 inhibition109,110.
Nonspecific PDE inhibitors may inhibit multiple PDEs and interact with many proteins,
which may alter the efficacy of these compounds. For example, because the methylxanthine
theophylline is a purine derivative, it inhibits almost all PDEs and also interacts with many
other proteins, producing both beneficial and toxic effects31,111. Although the
bronchodilatory effects of theophylline are most probably related to PDE inhibition in the
airway smooth muscle, its anti-inflammatory actions — which are mediated in part via
inhibition of the nuclear translocation of nuclear factor-κB (NF-κB) — may be attributed to
both PDE inhibition (similar to the effects of the PDE4 inhibitor NCS 613)112 and to
increased cAMP signalling113,114, as well as to effects that are independent of this
activity111,115. Indeed, theophylline directly activates phosphoinositide 3-kinase δ-subunit
(PI3Kδ), which, in turn, activates histone deacetylases (HDACs) and thus augments the anti-
inflammatory effects of glucocorticoids111,115. Theophylline also binds to adenosine
receptors, and although blocking adenosine A2B receptors may be beneficial in preventing
adenosine-induced mediator release from mast cells, blocking adenosine A1 receptors could
account for serious untoward effects, including cardiac arrhythmias and seizures31,111. Last,
inhibition of PDE4 could account, in part, for theophylline-induced nausea and
diarrhoea31,111.
New uses, drugs and development approaches
The enormous clinical success of PDE5 inhibitors has spurred continued interest in PDE
inhibitors as potential therapeutics as well as in approaches to overcome the limitations of
current PDE inhibitors. In addition, the emerging concept that many individual PDEs or
subsets of PDEs are selectively localized or recruited to specific cellular compartments
where they are integrated into specific signalosomes provides insight into their specific
functional roles in health and disease, as well as their potential as novel therapeutic targets.
The level of interest in PDE inhibitors can be readily appreciated from the large number of
clinical trials registered on the ClinicalTrials.gov website; some of these trials are listed,
along with their indications and associated NCT designations, in TABLE 4. Many of these
trials are in Phase IV, involve US Food and Drug Administration (FDA)-approved PDE3,
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PDE4 and PDE5 inhibitors, and are designed to provide additional information about the
efficacy of these inhibitors in subpopulations of currently targeted patients or in novel
clinical applications (TABLES 2,4). In addition, a substantial number of trials (TABLE 4)
are investigating novel PDE inhibitors in the treatment of diseases for which PDE inhibitors
are already approved — that is, COPD, pulmonary hypertension and erectile dysfunction —
or for additional diseases. Trials investigating the use of PDE1 inhibitors for the treatment of
vascular remodelling or schizophrenia, PDE7 inhibitors for the treatment of inflammation or
leukaemia, and PDE10A inhibitors for the treatment of neuropsychological disorders are all
in progress. Because of the complexity of many diseases, such as COPD, asthma and type 2
diabetes, there is also increasing interest in utilizing multiple PDE inhibitors or developing
inhibitors that target several particular PDEs to provide more effective therapies with more
favourable risk–benefit profiles.
Novel applications of PDE inhibitors
PDE3 inhibitors
A substantial number of trials are testing currently approved PDE inhibitors in other
conditions (TABLE 4). For example, clinical studies have suggested that the PDE3 inhibitor
cilostazol, perhaps owing to its anti-inflammatory effects as well as its ability to inhibit
platelet aggregation and vascular smooth muscle proliferation100, may attenuate post-
angioplasty restenosis (the ‘cilostazol for restenosis’ (CREST) trial)116–118 or reduce the
progression of atherosclerosis in diabetes (the randomized ‘diabetic atherosclerosis
prevention by cilostazol’ (DAPC) trial)119,120. The vascular smooth muscle cell (VSMC)-
proliferation-stimulating component of this potential activity is underpinned by data
obtained using VSMCs derived from Pde3a-null mice121. Aortic VSMCs of Pde3a-deficient
mice, but not those from Pde3b-null mice, exhibited dysregulated cAMP–PKA signalling
and mitogen-activated protein kinase (MAPK) signalling as well as reduced mitogen-
induced VMSC proliferation121.
PDE1 may also be a crucial regulator of pathological vascular and airway smooth muscle
remodelling105. In normal vessels, VSMCs exhibit a quiescent or contractile phenotype,
which is geared to maintain vascular tone. In response to injury and/or endothelial
dysfunction, VSMCs shift to a synthetic or proliferative phenotype in which the induction of
PDE1C removes the inhibitory effects of cAMP on growth. siRNA-induced knockdown of
PDE1A or pharmacological inhibition of PDE1A with IC83640 (a PDE1-selective inhibitor)
blocked cell cycle progression in proliferating VSMCs105. Similarly, PDE1C knockdown in
VSMCs derived from pulmonary hypertensive arteries increased cAMP and inhibited
proliferation105. Thus, targeting PDE1C105 and/or PDE3A121 in vessels might, via increased
cAMP signalling, block the growth of VSMCs and reduce the vascular remodelling that
occurs in pulmonary hypertension, atherosclerosis, post-stenting restenosis and after
angioplasty, as well as certain cardiomyopathies.
PDE4 inhibitors in inflammatory disorders
Given their potent anti-inflammatory effects, PDE4 inhibitors might be useful for treating
diseases involving aberrant immune responses, such as atopic dermatitis, rheumatoid
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arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease and type 1
diabetes29–31,35,122,123. As shown in TABLE 4, apremilast — a second-generation PDE4
inhibitor — is in Phase II and Phase III trials for use in psoriasis and psoriatic arthritis31,123.
Studies with Pde4a-, Pde4b- and Pde4d-null mice124–126 demonstrated that only the Pde4b-
null mice failed to develop airway inflammation (that is, T helper 2 (TH2) cytokine
production and eosinophil infiltration) or acute airway hyperactivity in response to antigen-
induced challenge92. Other findings are consistent with the idea that inhibition of PDE4D in
particular, rather than other PDE4 isoforms, is associated with the dose-limiting
gastrointestinal side effects of PDE4 inhibitors, whereas PDE4B seems to have an important
role in acute activation of the T cell receptor (TCR)124–127. Studies such as these have
provided the rationale for the development of PDE4B-selective inhibitors as potential
therapeutics for allergic inflammation and asthma92, and the development of PDE4D-
selective allosteric modulators (as discussed below) to reduce inflammation and improve
cognition35.
Recent studies exploring the biology of the nonspecific PDE inhibitor resveratrol128,129 may
have important implications for future clinical applications of PDE4 inhibitors. In animal
models, resveratrol — a polyphenol found in red wine — protects against diet-induced
obesity, type 2 diabetes and some of the cardiovascular complications associated with these
disorders128. Indeed, recent findings have suggested that many of the pleiotropic beneficial
effects of resveratrol may be mediated via its nonspecific inhibition of PDEs, especially
PDE4, as the metabolic benefits of resveratrol in mice129 were mimicked by the inhibition
of PDE4 with rolipram. Indeed, when compared to littermates that were fed a high-fat diet,
Pde4b-knockout mice gained less weight and had less obesity-induced inflammation130.
Perhaps more importantly, significant weight loss was reported in participants receiving
roflumilast in clinical trials30. Roflumilast has also recently been reported to reduce levels of
glycated haemoglobin and blood glucose in patients with newly diagnosed type 2
diabetes131. Thus, PDE inhibitors, especially PDE4 inhibitors, may be useful for treating
certain metabolic diseases, including obesity, type 2 diabetes and metabolic syndrome132.
Given the current understanding of the crucial role of inflammation in these diseases133, the
anti-inflammatory actions of PDE4 inhibitors may provide considerable therapeutic benefit.
PDE5 inhibitors
Clinical trials (TABLE 4) are in progress investigating PDE5 inhibitors in heart failure as
well as in Duchene and Becker muscular dystrophy (the ‘Revatio for Heart Disease in
Duchenne and Becker Muscular Dystrophy’ REVERSE-DBMD trial). Indeed, there is
considerable excitement regarding the potential use of PDE5 inhibitors as therapeutics for
cardiovascular diseases102, including hypertension, ischaemic cardiomyopathy, cardiac
failure, stroke, peripheral myopathy and cardiac dysfunction in Duchenne muscular
dystrophy, as well as insulin resistance, type 2 diabetes and metabolic
syndrome33,34,98,102,103,132,134–136.
In rodent heart models of ischaemia–reperfusion injury, sildenafil has a cardioprotective
effect and limits infarct size, perhaps by increasing cGMP–PKG signalling, which results in
the opening of mitochondrial ATP-sensitive potassium channels, thus limiting the
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accumulation of calcium in mitochondria and preventing cell death102. In the rodent heart,
sildenafil blocked the development of cardiac hypertrophy induced by trans-aortic
constriction or by the β-adrenergic receptor agonist isoprenaline. Remarkably, in the mdx
mouse model of Duchenne muscular dystrophy, sildenafil prevented or reversed the cardiac
dysfunction and cardiomyopathy characteristically observed in these mice. Similar to their
effects on pulmonary circulation, PDE5 inhibitors may improve cerebral circulation and
oxygenation and thus protect the brain against stroke102.
PDE10 inhibitors and other PDE inhibitors in nervous system disorders
PDE10 inhibitors are being considered as cognition enhancers and as therapeutics for
cognitive dysfunction, based on preclinical studies that have demonstrated the beneficial
effects of these agents on learning and memory as well as on cognitive and behavioural
defects in complex neuropsychological disorders such as schizophrenia. As of 2012, for
example, ~25 PDE4 inhibitors and ~10 PDE10A inhibitors had been granted patents that
claimed a positive effect on learning and memory137. Another report138 indicated that more
than 20 companies had published patent applications targeting PDE10A for central nervous
system (CNS) research purposes, especially schizophrenia41,42,93. PDE10A inhibitors,
which have been shown to have antipsychotic effects in rodent models41,42,138 and to exhibit
antipsychotic and pro-cognitive effects as well as enhance social behaviour in mice139, are
in clinical trials for the treatment of schizophrenia (TABLE 4). A PDE1 inhibitor, ITI-214,
is in trials for the treatment of cognitive deficits associated with schizophrenia and other
neuropsychiatric disorders140. Other companies are also developing PDE inhibitors to target
these diseases (TABLE 4). There is also interest in utilizing inhibitors of PDE10A and
PDE4 in Huntington’s disease93,141 (TABLE 4).
Combinatorial PDE inhibition
Although individual PDEs regulate selective cAMP signalling pathways, the dysregulation
of multiple signalling pathways contributes to the pathogenesis and clinical presentations of
complex diseases such as COPD and diabetes142,143. It is therefore likely that several PDEs
may need to be targeted for effective treatment. Targeting multiple PDEs (with multiple
drugs or with individual drugs that have mixed selectivities) in several target cells could
theoretically produce additive or synergistic effects and lead to more effective therapies, so
that drugs could perhaps be administered at lower doses and induce fewer side effects
(TABLES 2,4). Novel second-generation, non-selective PDE inhibitors (analogous to
theophylline and resveratrol) might also provide simultaneous inhibition of multiple PDEs
and the activation of several signalling pathways, thereby producing additive or synergistic
beneficial effects in these and other complex diseases.
A major impetus to consider dual PDE inhibitor therapy relates to the desire to take full
advantage of the powerful anti-inflammatory effects of PDE4 inhibitors, such as roflumilast,
as the narrow window between their anti-inflammatory effects and their side effects (which
include nausea and emesis) may limit their application in many inflammatory diseases. The
anti-inflammatory effects of PDE4 inhibitors are not identical in all immunoinflammatory
cells, and inhibitors of PDE7 and PDE3 can enhance the effects of PDE4 inhibitors in T
cells and macrophages, respectively31,143,144. With respect to diseases such as asthma,
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PDE4 inhibitors are not broncho- or vasodilators. Thus, although new PDE4 inhibitors with
reduced emetic effects are in development (for example, the PDE4D allosteric modulator
D159687)31,35, a combinatorial approach could maximize the efficacy of PDE4 inhibitors
without adversely affecting their risk–benefit ratios143,145.
Dual PDE8–PDE4 inhibitors
Studies utilizing family-selective PDE8 inhibitors, as well as studies using Pde8a-knockout
mice, Pde8b-knockout mice and Pde8a−/−Pde8b−/− double-knockout mice, demonstrated
that PDE8A and PDE8B have both specific and overlapping roles in regulating the basal
rates of steroid production in rodent Leydig and adrenal cells76,77. PDE8 inhibitors,
however, clearly synergized with PDE4 inhibitors in regulating the maximal rates of cAMP-
stimulated steroidogenesis77. These studies clearly demonstrated that functionally
interacting cAMP pools or compartments can be regulated by multiple PDEs.
Dual PDE1–PDE4 inhibitors
There is evidence indicating that combined PDE1 and PDE4 inhibitors could have utility in
pathological airway remodelling (mediated by PDE1) and pulmonary inflammation105,143.
Airway remodelling (thickening of the wall owing to hyperplasia or hypertrophy) and
increased airway hyperreactivity are characteristic of the pro-inflammatory phenotypes of
asthma and COPD. PDE1 inhibitors block smooth muscle mitogenesis and could
complement the anti-inflammatory effects of PDE4 inhibitors105,143. KF19514, which
inhibits both PDE1 and PDE4, was reported to reduce airway remodelling and inflammation
in a murine model of asthma143,145.
Dual PDE4–PDE7 inhibitors
PDE7A is widely expressed in immunoinflammatory cells, especially T lymphocytes, but its
functional role is not certain, and selective PDE7 inhibitors do not markedly alter normal T
cell function143,144. However, the co-expression of PDE4 and PDE7 in most
immunoinflammatory cells and the synergistic effects of PDE7- and PDE4-selective drugs
in the suppression of inflammation in cell-based studies have fuelled speculation that dual
inhibition of PDE7 and PDE4 could be an effective strategy to treat asthma, COPD and
other diseases characterized by a pro-inflammatory phenotype143,146.
Dual PDE3–PDE4 inhibitors
As PDE3 inhibitors147 are bronchodilators and, similar to PDE7 inhibitors, they increase the
effects of PDE4 inhibitors in immunoinflammatory cells (especially macrophages)143,148,
several pharmaceutical companies have developed inhibitors with dual selectivity for PDE3
and PDE4 as potential therapeutics for asthma and COPD145,148,149 (TABLES 2,4). So far,
no lead scaffolds generated through structure-based design have been reported. Some
attempts have generated hybrid compounds with distinct PDE3 and PDE4 pharmacophores
separated by a linker149. Two early dual PDE3–PDE4 inhibitors (zardaverine and
benafentrine) had modest and short-lived bronchodilatory effects in humans150. Another
PDE3–PDE4 inhibitor, RPL554 (a pyrimido-isoquinolinone derivative with IC50 values of
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107 nM and 1.2 μM for PDE3 and PDE4, respectively), is in trials for COPD, allergic
rhinitis and asthma151.
Alternative approaches for targeting PDE4 in pulmonary disease include the development of
inhaled PDE4 inhibitors or inhaled antisense oligonucleotides targeting specific PDE4
isoforms, as well as combinations of PDE4 inhibitors and inhaled corticosteroids or β-
adrenergic receptor agonists. For example, the inhaled PDE4 inhibitor GSK256066
significantly reduced early and late responses to inhaled allergen in a small trial studying 24
patients with asthma152. In COPD, roflumilast can be used alone or together with standard
bronchodilator treatments, such as salmeterol (a long-acting β2-adrenergic receptor agonist
(LABA)) or tiotroprium (a short-acting anticholinergic drug)30,145.
Novel signalosome disruptors
As discussed above, individual PDEs are recruited in an isoform-specific manner into
specialized signalosomes within discrete functional compartments, where they can tightly
regulate local cyclic nucleotide concentrations and gradients13,153 (TABLE 3). As a
corollary to the signalosome hypothesis, there are data supporting the therapeutically
relevant proposition that the disruption of cyclic nucleotide-mediated events within specific
individual signalosome-based compartments will have more specific effects than agents that
do not discriminate between these compartments and instead inhibit other members of the
same PDE family9,61–65.
It should be possible to target events that are coordinated by individual signalosomes. This
could be achieved by disrupting the integration of individual proteins into these
signalosomes during their formation or, more conceivably, by displacing individual proteins
from pre-formed or dynamically forming signalosomes in cells using small-molecule
antagonists154,155 or ‘disruptor peptides’156 to antagonize protein–protein interactions.
Examples of small molecules or peptides include those designed to displace PKA regulatory
subunits from AKAPs154,155 or other scaffolding proteins156–159, peptides designed to
antagonize the interaction of PDEs with cyclic nucleotide effectors19,57, and peptides
designed to disrupt PDE–EPAC interactions57,62,63 (FIG. 4).
Peptide-based therapeutic agents have some advantages over traditional small-molecule
drugs, such as their high potency and selectivity, their low toxicity and biological
accumulation in tissues as well as their high diversity. Conversely, their physicochemical
properties make them unsuitable for simple oral delivery, and without modification they
have relatively poor bioavailability and low metabolic stability. Indeed, small unconjugated
linear peptides composed exclusively of natural amino acids are easily degraded by
numerous peptidases and are efficiently removed from the circulation by the kidney.
However, although these disadvantages have limited the use of peptide-based therapeutics,
recent advances with the potential to dramatically enhance the membrane permeability and
metabolic stability of these agents are increasingly enabling their clinical use160.
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Disruptors of targeted PDEs
PDE4
In human arterial endothelial cells (HAECs), the inhibitory effects of cAMP on cell
permeability, mediated via the activation of EPAC1–RAP1 (small GTPase RAS-related
protein 1) signalling, are regulated through a PDE4D-containing, EPAC1-based, cAMP
signalo-some57,62,63 (FIG. 4). The use of traditional PDE4 inhibitors (such as rolipram and
Ro20-1724) or an EPAC1-based PDE4D-disrupting peptide led to the activation of RAP1 by
EPAC1 within this complex and promoted HAEC barrier integrity (FIG. 4). Further studies
are needed to assess the impact of disrupting PDE4D- or EPAC1-mediated endothelial
barriers in vivo under conditions of vascular inflammation. Similarly, in isolated
cardiomyocytes, a peptide that selectively disrupted the association of PDE4D5 with heat
shock protein 20 (HSP20) increased local cAMP–PKA-induced phosphorylation of HSP20
and reduced the catecholamine-induced hypertrophic response in this model system19,161.
Such an approach could have utility in limiting cardiac hypertrophy, and studies to test this
hypothesis are underway.
Although these studies highlight the functional consequences of disrupting these complexes
in cells, further studies will be required to assess their functional selectivity in more
physiological settings. Indeed, in the context of displacing PDE4D5 in cardiomyocytes, this
approach might be limited by potentially arrhythmogenic effects resulting from cAMP–
PKA-induced hyperphosphorylation of the L-type calcium channel (BOX 2). In this context,
studies with Pde4b-knockout mice highlight the potential benefits of targeting PDE4B-
containing signalosomes in immunoinflammatory cells in conditions including COPD and
asthma92,162, as opposed to the potentially arrhythmogenic effects of targeting PDE4B-
containing signalosomes in cardiomyocytes (BOX 2). Finally, in a breast cancer cell model
system, a peptide that selectively blocked the interaction between PDE4D5 and the scaffold
protein RACK1 — in a complex composed of focal adhesion kinase (FAK), RACK1 and
PDE4D5 — inhibited the invasion potential of the cultured cancer cells and might provide a
novel avenue for limiting the invasion of certain cancer cells157.
PDE3
In the same HAEC cultures in which barrier function was shown to be locally regulated by a
PDE4D- and EPAC1-based signalosome, a PDE3B-containing, EPAC1-based cAMP
signalosome was also shown to selectively coordinate the effects of cAMP on HAEC
adhesion, migration and tubule formation via the control of RAS-related protein (RRAS)
and PI3Kγ signalling57 (FIG. 4). As with the PDE4D–EPAC1 complex that regulated HAEC
permeability, the addition of either a PDE3 inhibitor (cilostamide) or of a PDE3B-based
EPAC1-disruptor peptide promoted cAMP-mediated activation of RRAS and the RRAS-
dependent activation of PI3Kγ62,63. Further studies will be required to determine how this
avenue might be used to control angiogenesis in both wound healing and metastasis.
PDE8A
Recently, a crucial role was identified for the formation of a PDE8B–RAF1 complex in the
control of PKA-dependent phosphorylation and inactivation of RAF1 in cells. Brown and
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co-workers65 reported that a PDE8A-based RAF1-disrupting peptide promoted PKA-
mediated phosphorylation of RAF1 in cells and thus provided mechanistic insights into the
manner by which localized hydrolysis of cAMP has a crucial role in PKA-mediated
phosphorylation and inhibition of RAF1. Given the importance of RAF1-mediated
signalling in numerous systems, this mechanism may allow selective regulation of RAF1
activity in cells in which the actions of RAF1 are maladaptive, such as certain cancers.
Although we are only now beginning to identify where PDE-based signalosomes form and
operate in cells, based on these examples it is likely that disrupting peptides, or small
molecules with similar types of activities, will prove to be fruitful new therapeutic tools in
the near future (TABLE 3).
Allosteric modulators
N-terminal regulatory domains in certain PDEs contain structural determinants that are
essential for PDE oligomerization, and although some of these have been suggested to
regulate the catalytic activity of PDEs, these regions have not yet been targeted in the
development of PDE activators or inhibitors. For instance, PDE2, PDE5 and PDE6 family
enzymes contain homologous N-terminal GAF domains (FIGS 1,5a), which, upon cGMP
binding, promote cyclic nucleotide hydrolysis via allosteric regulation of the distant C-
terminal catalytic domain3,46. Similarly, two N-terminal domains, termed upstream
conserved region 1 (UCR1) and UCR2 (FIGS 1,5b,c), form a functional module that
regulates the catalytic activity of PDE4 as well as its oligomerization3,46,163. In this case,
however, UCR-based regulation involves direct interactions between the UCR and the
catalytic domain. A novel approach in the design of specific PDE inhibitors has focused on
developing modulators that target and alter the interactions between N-terminal regulatory
domains and their downstream catalytic domains.
GAF domain-based regulation
Crystallographic data of homodimeric PDE2A (FIG. 5a) showed that unliganded PDE2A
GAF domains (GAFA and GAFB) are arranged to form a parallel dimer that hinders the
access of substrates to both catalytic domains of the dimeric PDE2A complex18,164. By
contrast, the binding of cGMP to GAFB in PDE2A promoted the rotation of the monomeric
catalytic domains, the removal of GAF-dependent steric hindrance and subsequent binding
of the substrate18,164 (FIG. 5a). Using this information, a chimaera was constructed in which
the GAF domains of PDE5A were fused to the cGMP- and GAF-regulated cyanobacterial
adenylyl cyclase (CyaB1), and this chimaera was used in a high-throughput screen to
identify compounds that inhibited GAF-mediated activation of CyaB1 by cGMP, but not
cGMP-independent cyclase activity165. At least two specific GAF inhibitors, which blocked
cGMP-induced activation of CyaB1, but not the intrinsic catalytic function of the cyclase,
were discovered and are being characterized165.
UCR-based regulation
Although the cAMP binding pockets of PDE4 subfamilies (PDE4A, PDE4B, PDE4C and
PDE4D) exhibit subtle conformational differences38, the variation within these active sites is
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small. As a result, PDE4 subfamily selectivity cannot be achieved just by targeting the
active site. Analyses of crystal structures of PDE4B or PDE4D in complex with certain
inhibitors, such as RS25344, have indicated that a UCR2 fragment interacts with the
inhibitor at the active site, allowing for direct regulation of catalytic activity by the UCR2
domain35,163. Crystallographic studies have identified three distinct homodimeric
conformations of PDE4 subfamily enzymes. In the ‘open’ conformation, each active site has
direct access to cAMP and functions independently38,163. As all PDE4 subfamily enzymes
have a highly conserved active site, therapeutic agents that target this open conformer,
including roflumilast, act as non-selective competitive inhibitors of all PDE4 enzymes
(TABLE 2). In their ‘closed’ conformation, a C-terminal intramolecular helix in all PDE4
enzymes loops across the active site of each monomer to gate the access of cAMP to the
catalytic site and to inhibit cAMP hydrolysis. In a third conformation, a UCR2-based helix
from one monomer folds across and ‘caps’ the active site of the second monomer, and thus
inhibits cAMP hydrolysis by the second monomer in ‘trans’15,163 (FIG. 5b,c). The
equilibrium between the ‘capped’ and ‘uncapped’ states is influenced by extracellular
signal-regulated kinase (ERK)-induced phosphorylation and specific inhibitors.
Structures of PDE4B or PDE4D3 in complex with certain inhibitors, including RS25344,
have shown that RS25344 binds to the active site but also forms contacts with a helical
fragment in the UCR2 domain. These interactions between UCR2 and RS25344 increased
the affinity of the inhibitor for the PDE4D3 active site35,47,163 (FIG. 5b,c). UCR-mediated
regulation of PDE4 activity is further regulated by the complex series of post-translational
events and protein–protein interactions that PDEs are known to participate in13,92. It should
be noted, however, that although interactions between UCR2 and certain PDE4 inhibitors at
the active site induce conformational changes that result in an increased affinity of the
inhibitor at the active site, UCR-mediated regulation involves physical ‘capping’ and
interactions at the active site and thus does not induce classical allostery. Classical allostery
involves conformational changes and the transduction of intra-molecular signals to the
active site that arise through the interactions of ligands at regulatory sites that are distinct
from the active site.
These multiple models have informed the development of PDE4D subtype-selective
modulators that act as ‘bidentate ligands’ and bind simultaneously to both UCR2 and the
active site to hold UCR2 in the closed position and partially inhibit PDE4 activity35,47,163.
PDE4D subtype-selective inhibitors were designed by targeting a phenylalanine (in PDE4D)
or tyrosine (in PDE4B) polymorphism in the UCR2 domain. One such PDE4D-selective
allosteric regulator, D159687, was demonstrated to have potent anti-inflammatory effects in
cell models and animal models, with minimal emesis, which suggests that it could have
utility in inflammatory conditions such as COPD, asthma, psoriasis and arthritis35,163. In
addition, studies in mice suggest that compounds like D159687 may have applications in
improving cognitive function and memory, as well as in the treatment of depression. Based
on this work, similar allosteric modulators acting at the UCR2 domain of PDE4B and the
catalytic site of PDE4B might provide effective suppression of inflammation in
asthma35,47,163. As sequences of the N-terminal regulatory domains vary considerably
across PDE families and subfamilies, it is anticipated that, given these early successes with
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allosteric modulators of PDE4, similar approaches aimed at antagonizing or promoting
direct interactions between regulatory domains and catalytic sites in other PDEs will soon be
underway.
Concluding remarks
Why are there so many PDEs? This question has been posed since the 1970s, well before the
advent of molecular genetics. Based on the findings reviewed in this article, the signalosome
concept has, in many respects, helped to provide the answer. Indeed, we suggest that the
information reviewed herein is consistent with the notion that the tethering or targeting of
individual PDEs to selected signalosomes at different subcellular locations allows individual
PDEs to assume specific functional roles in the compartmentalized regulation of specific
cyclic nucleotide signalling pathways, as well as physiological and pathophysiological
responses. Moreover, as discussed above, we believe that by targeting individual
signalosomes it will be possible to develop novel strategies to treat many diseases.
In addition, an increased understanding of the complexities of PDE biology, especially from
the use of knockout and knockdown models of specific PDEs, has identified new targets for
old and new drugs. These include PDE5 inhibitors for cardiovascular and metabolic
diseases, PDE1C and PDE3A inhibitors for vascular remodelling, PDE1 and PDE10A
inhibitors for schizophrenia, PDE7 inhibitors for inflammation, PDE4 inhibitors for
diabetes, as well as PDE inhibitors in combination with other therapeutic modalities. This
increased knowledge has also provided a conceptual framework for using multiple PDE
inhibitors, inhibitors with mixed selectivities or non-selective inhibitors for complex
diseases (TABLES 1,2,4).
As described above, the design of novel selective inhibitors is being increasingly driven by
this improved understanding of the biology of PDEs and PDE inhibitors, as well as by
structural insights from modern proteomics and X-ray crystallography of PDE catalytic
cores and PDE–inhibitor co-crystal complexes, in addition to more complex structures.
These studies have yielded information about the unique allosteric interactions between the
regulatory and catalytic domains of PDEs, as well as between individual PDEs and their
specific interacting partners (FIGS 4,5; TABLES 2–4). The design and delivery of novel
selective agents, especially allosteric modulators (for example, PDE4D-selective inhibitors)
and signalosome disruptors, will be challenging, but offers huge opportunities for the
development of more specific and effective therapeutics.
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(PDE). A large gene superfamily of isozymes that catalyse the
hydrolysis of the important intracellular messengers cAMP and
cGMP
Signalosomes Localized macromolecular complexes, formed via protein–protein
interactions, that contain cyclic nucleotide effectors and regulate
the subcellular compartmentalization of specific cyclic nucleotide
signalling pathways. The incorporation of specific
phosphodiesterases (PDEs) into signalosomes has established the
crucial roles of individual PDEs in regulating specific cyclic
nucleotide signalling pathways. This knowledge has spurred the
development of more sophisticated strategies to target individual
PDE variants and their interacting partners
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Figure 1. Structure and domain organization of 11 mammalian PDE families
The conserved catalytic domain (shown in red) is located in the carboxy-terminal portion of
the phosphodiesterases (PDEs). The catalytic domain of PDE3 contains a unique 44-amino-
acid insert (shown in black). Many of the PDE families1–3 contain amino-terminal
subdomains (such as GAF domains, transmembrane domains, targeting domains, upstream
conserved regions (UCRs), PAS domains and REC domains) and N-terminal hydrophobic
regions that are important in subcellular localization, in the incorporation of PDEs into
compartmentalized signalosomes, in interactions with signalling molecules and molecular
scaffolds, and in the regulation of PDE activity. GAF domains regulate the allosteric binding
of cGMP (to PDE2, PDE5, PDE6 and PDE11), the allosteric binding of cAMP (to PDE10)
and the regulation of catalytic activity (in PDE2, PDE5 and PDE6). Phosphorylation sites
are labelled on the figure. CaMKII, calcium/calmodulin-dependent protein kinase II; ERK2,
extracellular signal-regulated kinase 2; PKA, protein kinase A; Pat7, 7-residue nuclear
localization signal.
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Figure 2. Binding of substrates and inhibitors to the active site of PDEs
a | Interaction of the substrates cAMP (green sticks) and cGMP (yellow sticks) with the
D674A mutant of phosphodiesterase 10A2 (PDE10A2). Residues from the structures of
PDE10A2–cAMP and PDE10A2–cGMP are shown in cyan and pale orange, respectively.
Binding to Zn2+ was lost owing to the D674A mutation. Substrates of cAMP and cGMP
have the same syn-conformation, but opposite orientations. b | Surface presentation of the
binding of cAMP and cGMP to the D674A mutant of PDE10A2. c | Surface presentation of
PDE4D2 binding to roflumilast (green stick). d | Ribbon diagram of PDE4D2 bound to
roflumilast. ‘H’ represents the helical loops in the catalytic core. See REFS 15,16,36,40 for
more information.
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Figure 3. PDE-containing signalosomes couple cAMP–PKA signalling to myocardial contractility
Phosphodiesterase 4B (PDE4B), as a component of an A-kinase anchor protein 15/18
(AKAP15/AKAP18α)-based signalosome in the cardiac L-type calcium channel (LTCC)
complex, regulates the calcium current and protects against ventricular arrythmias in
mice167. AKAP6 (also known as mAKAP) serves as a scaffold for a PDE4D3-containing
signalosome that is involved in regulating the release of calcium from the sarcoplasmic
reticulum via the ryanodine receptor channel168. PDE3A, as a component of a sarcoplasmic/
endoplasmic reticulum calcium ATPase (SERCA) AKAP18δ-containing signalosome, is an
important regulator of the effects of cAMP on calcium uptake into the sarcoplasmic
reticulum169. NCX, sodium/calcium exchanger; PKA, protein kinase A; PKA-C, PKA
catalytic domain; PKA-R, PKA regulatory domain; PLB, phospholamban; PMCA, plasma
membrane calcium-transporting ATPase; PP2A, protein phosphatase 2A; Rg, PP2A
regulatory subunit; TNNC, troponin C; TNNI, troponin I.
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Figure 4. Human arterial endothelial cells construct two distinct PDE- and EPAC-based
signalosomes to regulate, spatially and functionally, integrin- and vascular endothelial cadherin-
based adhesions, respectively
As shown in the top panel, a direct interaction between phosphodiesterase 3B (PDE3B) and
exchange factor directly activated by cAMP (EPAC) promotes the formation of a plasma
membrane signalosome that controls cAMP-mediated activation of RAS-related protein
(RRAS) and its subsequent activation of the p84-regulatory domain-associated p110γ
subunit of phosphoinositide 3-kinase γ and, ultimately, integrin-based adhesions with the
extracellular matrix. A PDE3B-based, EPAC1-displacing peptide antagonizes PDE3B–
EPAC1 protein–protein interactions (PPIs), allows localized increases in cAMP and
promotes signalling through this signalosome62. As shown in the bottom panel, a direct
interaction between PDE4D and EPAC1 promotes the integration of these proteins into a
vascular endothelial cadherin-based signalosome that allows cAMP — acting through
EPAC1-based activation of small GTPase RAS-related protein 1 (RAP1) — to regulate
endothelial cell permeability. An EPAC1-based, PDE4D-displacing peptide antagonizes
PDE4D–EPAC1 PPIs, interferes with the integration of these proteins into the signalosome
and increases endothelial cell permeability63. HAEC, human arterial endothelial cell; PIP3,
phosphatidylinositol-(3,4,5)-trisphosphate; PKB, protein kinase B.
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Figure 5. Allosteric modulation of PDE2 and PDE4
a | Ribbon diagram of near-full-length unliganded phosphodiesterase 2A (PDE2A). The
entire molecule A of the PDE2A dimer is shown in green, whereas GAF domain A (GAFA)
is shown in magenta, GAFB in yellow and the catalytic domain of molecule B in pale
pink18,164. b | Ribbon diagram of the PDE4 catalytic domain (shown in pale cyan) with an
upstream conserved region 2 (UCR2) fragment (shown in green). The PDE4-selective
inhibitor RS25344 (shown in yellow) binds to the active site of PDE4 and also interacts with
the UCR2 fragment. c | Detailed view of the interaction of RS25344 (shown in yellow) with
PDE4D3 residues (shown in cyan and green; Protein Data Bank ID: 3G4G). Similar to other
PDE4 inhibitors, the allosteric modulator RS25344 forms a conserved hydrogen bond with
the invariant Gln535 and stacks against Phe538 in the catalytic pocket. However, RS25344
makes unique hydrophobic contacts with Phe196 and Val200 in the UCR2 helix, which
‘caps’ and interacts with the active site35,163.
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Table 1
PDE tissue expression and impact of knockout in mice




PDE1B (two variants), PDE1C
(five variants)
Broad; significant in cardiac and vascular
myocytes, central and peripheral neurons,
lymphoid (T and B cells) and myeloid cells
(macrophages have higher expression levels
than monocytes) as well as in testes and
sperm1–3
• PDE1B: increased exploratory behaviour,
learning deficits, hyperactivity174
• PDE1C: regulation of olfaction175
PDE2 (cGMP-activated):
PDE2A (four variants)
Broad; significant in the brain, heart
(myocytes), liver, adrenal cortex,
endothelium and platelets1–3,46




Broad; significant in cardiac and vascular
myocytes, brain, liver, adipose tissues,
pancreatic β-cells, endothelium, epithelium,
oocytes and platelets1–3,46,66–67
• PDE3A: female infertility owing to oocyte
meiosis arrest67; dysregulated vascular myocyte
proliferation121




PDE4B (four variants), PDE4C
(seven variants), PDE4D (nine
variants)
Broad; significant in cells of the
cardiovascular, neural, immune and
inflammatory systems1–3,46
• PDE4A: no phenotype177
• PDE4B: reduced TNF response to LPA124
• PDE4C: none published
• PDE4D: delayed growth, impaired ovulation,





Broad; significant in vascular myocytes,
diseased cardiac myocytes, lung, brain,





PDE6A (one variant), PDE6B
(one variant), PDE6C (one
variant)







Broad in tissues including spleen, brain,
lung and kidney as well as in lymphoid and
myeloid cells1–3,46
• PDE7A: normal T cell activation; elevated
antibody response to a T cell-dependent
antigen178
• PDE7B: none published
PDE8 (cAMP-specific,
rolipram/IBMX-insensitive):
PDE8A (five variants), PDE8B
(six variants)
Broad; significant in testes (PDE8A) and
thyroid (PDE8B)1–3,46,76
• PDE8A: increased Leydig testosterone release;
increased sensitivity to luteinizing hormone77;
regulation of excitation–contraction coupling and
calcium transients in cardiomyocytes179
• PDE8B: enhanced memory and age-related




Broad; significant in spleen, brain and
intestinal cells1–3,46
• PDE9A: on high-fat diet, knockout mice
demonstrated reduced insulin resistance, reduced
weight gain and lower fat mass181; PDE9A




Expression limited to brain and
testes1–3,46,183
• PDE10A: decreased exploratory behaviour,
hypoactivity, delayed acquisition of conditioned
avoidance behaviour; female PDE10A-null mice
are smaller184
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PDE family or gene Tissue expression Knockout mouse phenotypes
PDE11 (cGMP-activated; four
variants)
Expression limited to prostate, testes and
salivary and pituitary gland1–3,46,185
• PDE11A: enlarged lateral ventricles; abnormal
behaviour186
CNS, central nervous system; E17, embryonic day 17; IBMX, isobutyl-1-methylxanthine; LPA, lysophosphatidic acid; PDE, phosphodiesterase;
TNF, tumour necrosis factor.
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Table 2
Selective inhibitors of PDEs
Selective inhibitor IC50 (nM) Physiology Potential therapeutic applications
PDE1
IC224 (ICOS)* 80 • Cardiac and vascular myocyte
contractility and
proliferation105,106,187,188
• Monocyte and macrophage
differentiation189
• Acrosomal reaction190














• NMDA receptor-induced LTP196


























• Obesity and satiety176,200





Rolipram 1,000 • Regulation of immune and
inflammatory cell functions29,142
• CNS effects affecting cognition
and mood92,93,201
• Airway myocyte relaxation202,203
• Apoptotic cell death in malignant
cells (DC-TA-46)204
• Inflammation29,142




• Pulmonary inflammation, asthma
and COPD202,203,205,206
• IBD (tetomilast; Phase III)208








AWD 12–281 (Elbion/GSK) 10
Apremilast (Celgene) 74
Quinolyl oxazole‡ (Merck) 0.06
DC-TA-46 10
PDE5
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Selective inhibitor IC50 (nM) Physiology Potential therapeutic applications
Zaprinast 500–700 • Relaxation of vascular, airway and
gastrointestinal
myocytes1–3,46,103,135
• Raynaud’s syndrome, COPD,
heart failure, cognition
enhancement1–3,46,103,135




• PAH (sildenafil, tadalafil; both
approved)103,215











None available – • Key role in visual transduction
(PDE6A and PDE6B mutations
associated with blindness)68
• Several PDE5 inhibitors (for
example, sildenafil) tightly bind to




ASB16165 (Asubio) 15 • Inhibition of immunoinflammatory
responses216,217
• ASB16165 inhibits T lymphocyte
activation and suppresses skin
inflammation216
• Selective PDE7 inhibitors (such as
BRL-50481 and IR-202) and the
dual PDE4–PDE7 inhibitor
(IR-284) increased cAMP–PKA






BRL 50481 (GSK) 180
PDE8
PF-04957325‡ (Pfizer) 43 • Modulation of steroidogenesis,
lymphoid cell adhesion and
chemotaxis76,77,218




BAY73-6691 (Bayer) 55 • PDE9 inhibition improved learning
and memory in mice, and increased
apoptosis of some breast tumour
cells219,220
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Selective inhibitor IC50 (nM) Physiology Potential therapeutic applications
None available – • Inhibition of sperm motility230
• PDE11A-inactivating mutations in
patients with Cushing disease and
bilateral micronodular adrenal
hyperplasia80,81
• PDE11 gene defects and mutations
contribute to testicular and adrenal
tumours, Cushing disease and
psychiatric diseases231
• Fertility230
• Reduction of endocrine
neoplasia80,81
• Depression231
ACTH, adrenocorticotropic hormone; CLL, chronic lymphocytic leukaemia, COPD, chronic obstructive pulmonary disease; CNS, central nervous
system; GSK, GlaxoSmithKline; IBD, inflammatory bowel disease; LTP, long-term potentiation; NMDA, N-methyl-D-aspartate; PAH, pulmonary
arterial hypertension; PDE, phosphodiesterase.
*
The original developers of the inhibitors are indicated in parentheses; otherwise, they are commercially available.
‡
Structural information was used in the discovery of these inhibitors.
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Table 3
Compartmentalized PDE signalling in mammalian cells
PDE Subcellular compartment Potential signalling partners Cell function studies Refs
PDE1
PDE1A Perinuclear, nuclear CaM, PKG, EPAC Cardiac myocyte proliferation 232
PDE1C Lysosome CaM, CNGC, soluble adenylyl cyclase Myocyte collagen degradation 233
PDE2
PDE2A Mitochondria Soluble adenylyl cyclase (not tested
directly)
Respiration 234
PDE2A Plasma membrane Synaptophysin (not tested directly) Synaptic functions 235
PDE2A Plasma membrane PMCA4, nNOS, PKA-R2, RYR, L-type
calcium channels, PKG (not tested directly)
Cardiac contractility 236




PDE3A Plasma membrane PKA-R2–AKAP (not tested directly) Cardiac contractility 58
PDE3A Plasma membrane TRPC3, TRPC6, PKA-R2 (not tested
directly)
Vascular myocyte contractility 238
PDE3A ER SERCA2A, PLB, AKAP18δ, PKA-R2,
PP2A
Cardiac myocyte contractility 169
PDE3A Intracellular membranes BIG1, BIG2, PKA-R1 Vesicular transport 239
PDE3A Plasma membrane CFTR Epithelial electrical potential 240
PDE3A Plasma membrane, cytoplasm 14-3-3 Platelet aggregation 241
PDE3B Plasma membrane, cytoplasm 14-3-3β, PKA-R2, PKB PDE3B inactivation 242
PDE3B Insulin granules, plasma
membrane, ER
p85, PP2A, PKB, HSP90, IRS1, 14-3-3 Insulin-mediated lipolysis 243
PDE3B Plasma membrane EPAC1, p84–p110γ, RRAS Endothelial cell migration 62
PDE3B Plasma membrane p110γ, PKA-R2 Cardiac myocyte contractility 244
PDE4
PDE4A Plasma membrane p75NTR Regulated PAI1 expression 245
PDE4A Cytoplasm SQSTM1 N/A 246
PDE4A1 Cytoplasm, Golgi Phosphatidic acid-rich membranes N/A 247
PDE4A5 Plasma membrane AKAP3 Sperm motility 248
PDE4A Nuclear, mitochondria AKAP95, AKAP149, MTG T cell-regulated inflammation 249
PDE4A Plasma membrane, cytoplasm LYN N/A 250
PDE4A5 Plasma membrane, cytoplasm Immunophilin AIP N/A 251
PDE4B Mitochondria, centrosome DISC1, PDE4D, NDEL1, NDE1,
PAFAH1B1, tubulin, dynein, ATF4
Neural electrical potential 252,253





PDE4D Cytoplasm β-arrestin Cardiac function 255
PDE4D SR RHEB, mTOR Protein synthesis 256
PDE4D Golgi Myomegalin, PKA-R2 Cardiac myocyte contractility 257
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PDE Subcellular compartment Potential signalling partners Cell function studies Refs
PDE4D SR SERCA Cardiac myocyte contractility 258
PDE4D Proteosome PHD2 Protein degradation 259
PDE4D3 Plasma membrane AKAP18δ, AQP2 Water resorption 260
PDE4D3 Nuclear AKAP6, PKA-R2, PP2A, ERK5, EPAC1 Cardiac contractility 61,261
PDE4D3 ER RYR2, PKA-R2 Heart failure and arrhythmias 168
PDE4D3 Centrosome AKAP9, PKA-R2 (not tested directly) Cell division 64
PDE4D3 Plasma membrane RXFP1, β-arrestin, AKAP79 Relaxin-mediated signalling 262
PDE4D3 Plasma membrane KCNQ1, KCNE1, AKAP9, PKA-R2, PP1 Cardiac myocyte contraction 263
PDE4D3, PDE4D8, PDE4D9 Plasma membrane, cytoplasm AKAP5, AKAP12 Vascular myocyte migration 264
PDE4D4 Plasma membrane Spectrin Endothelial permeability 265
PDE4D4 Plasma membrane, cytoplasm SRC, LYN, FYN kinase (SH3 domains) Signalling 266
PDE4D5 Plasma membrane FAK, RACK1 Cell polarity and migration 157,159
PDE4D5, PDE4D7 Plasma membrane EPAC1, vascular endothelial cadherin, β-
catenin, p120-catenin, PKA-R2
Endothelial permeability 63
PDE4D5, PDE4D8, PDE4D9 Plasma membrane β2-adrenergic receptors, AKAP79,β-arrestin Cardiac myocyte contractility 267,268
PDE5
PDE5A Plasma membrane PKG (not tested directly) Cardiac myocyte contractility 269
PDE5A ER PKG1β, IRAG, InsP3 receptor 1 Platelet aggregation 270
PDE5A Cytoplasm PKA-R2, AKAPUnk (not tested directly) Cardiac contractility 237
PDE7
PDE7A Golgi MTG Inhibition of T cell activation 249
PDE7A Golgi, centrosome PKA catalytic domain Signalling 271
PDE8
PDE8A Mitochondria IκBβ, p105, p100 Signalling 272
PDE8A Cytoplasm RAF1 Signalling 65
14-3-3, 14-3-3 protein (YWHAQ); ADCY5, adenylyl cyclase 5; AIP, aryl hydrocarbon receptor interacting protein (also known as XAP2); AKAP,
A-kinase anchor protein; AQP, aquaporin; ATF4, activating transcription factor 4; BIG, Brefeldin A-inhibited guanine nucleotide exchange
protein; CaM, calmodulin; CFTR, cystic fibrosis transmembrane conductance regulator; CNGC, cyclic nucleotide gated ion channel; DISC1,
disrupted in schizophrenia homolog 1; EPAC, exchange factor directly activated by cAMP; ER, endoplasmic reticulum; ERK5, extracellular
signal-regulated kinase 5; FAK, focal adhesion kinase; GC, guanylyl cyclase; HSP90, heat shock protein 90; IκBβ, NF-κB inhibitor-β; InsP3,
inositol-1,4,5-trisphosphate; IRAG, inositol 1,4,5-trisphosphate-associated cGMP kinase substrate; IRS1, insulin receptor substrate 1; KCNE1,
potassium voltage-gated channel subfamily E member 1; KCNQ1, potassium voltage-gated channel, KQT-like subfamily, member 1; LYN, LCK/
YES-related novel protein tyrosine kinase; MTG, myeloid translocation gene; mTOR, mammalian target of rapamycin; N/A, not available; NDE1,
nudE neurodevelopment protein 1; NDEL1, NDE1-like protein 1; nNOS, neuronal nitric oxide synthase; p75NTR, p75 neurotrophin receptor;
PAFAH1B1, platelet-activating factor acetylhydrolase IB subunit-alpha; PAI1, plasminogen activator inhibitor 1; PDE, phosphodiesterase; PHD2,
prolyl hydroxylase domain protein 2; PKA, protein kinase A; PKA-R, PKA regulatory domain; PLB, phospholamban; PMCA4, plasma membrane
calcium-transporting ATPase 4; PP, protein phosphatase; RACK1, receptor of activated protein kinase C1; RHEB, RAS homolog enriched in brain;
RRAS, RAS-related protein; RXFP1, relaxin family peptide receptor 1; RYR, ryanodine receptor; SERCA, sarcoplasmic/endoplasmic reticulum
calcium ATPase 2; SQSTM1, sequestosome 1; SR, sarcoplasmic reticulum; TRPC, transient receptor potential channel. Detailed information
concerning interacting proteins and methods used to assess these interactions is included in Supplementary information S3 (table).
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Table 4
PDE inhibitors currently under clinical study
Agents (sponsors) Indication Status ClinicalTrials.gov identifiers
Pan-PDE
Resveratrol (US National Institute on Aging) Alzheimer’s disease Phase II NCT01504854
Resveratrol (American Diabetes Association) Impaired glucose tolerance Phase II NCT01375959
PDE1
ITI-214 (Takeda/Intra-Cellular Therapies) Schizophrenia Phase I NCT01900522
PDE2
PF-05180999 (Pfizer) Migraine Phase I NCT01981486
PDE3
Cilostazol (Universitair Ziekenhuis Brussel) Fertility Unknown NCT00823420
Cilostazol (Korea Otsuka Pharmaceutical) Chronic tinnitus Phase II NCT01378650
Cilostazol (Seoul National University Hospital) Dementia Phase IV NCT01409564
Cilostazol (Hanyang University) Atherosclerotic events Phase IV NCT00886574
Cilostazol (University of Southern California) Fertility Phase II NCT01915069
Cilostazol (Kobe City General Hospital) Restenosis Phase IV NCT01261234
Cilostazol (Korea Otsuka Pharmaceutical) Ischaemic stroke Phase IV NCT01013532
Milrinone (University of Nebraska/Thoratec
Corporation)
Heart failure Phase I NCT01571037
Enoximone (Gilead Sciences/AstraZeneca) Heart failure Phase III NCT00077948
PDE4
Rolipram (US National Institutes of Health) Depression Phase I NCT00369798
Rolipram (GlaxoSmithKline) Huntington’s disease Phase I NCT01602900
GSK356278 (GlaxoSmithKline) Huntington’s disease Phase I NCT01602900
ASP9831 (Astellas Pharma) Non-alcoholic steatohepatitis Phase II NCT00668070
GSK256066 (GlaxoSmithKline) Rhinitis Phase II NCT00464568
CHF6001 (Chiesi Farmaceutici) Asthma; COPD Phase II NCT01730404
Apremilast (Celgene) Ankylosing spondyloarthritis Phase III NCT01583374
Apremilast (Celgene) Acne Phase II NCT01074502
MK0952 (Merck Sharp & Dohme) Alzheimer’s disease Phase II NCT00362024
CHF6001 (Chiesi Farmaceutici) COPD Phase II NCT01730404
Roflumilast (Takeda) Atopic dermatitis Phase II NCT01856764
Roflumilast (Takeda) Dementia Phase II NCT01433666
Roflumilast (The National Heart, Lung and Blood
Institute)
Obesity Phase II NCT01862029
Sildenafil (University of Milan) Heart failure Phase III NCT00407446
Sildenafil, tadalafil (Cedars-Sinai Medical Center) Duchenne muscular dystrophy Phase I NCT01580501; NCT01359670
Sildenafil (IRCCS, San Raffaele) Endocrine function in patients with
diabetes
Phase III NCT00420901
Sildenafil (Vanderbilt University) Impaired glucose tolerance Phase III NCT01812434
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Agents (sponsors) Indication Status ClinicalTrials.gov identifiers
Sildenafil (University of Minnesota) Cardiac vasculopathy Phase II NCT01812434
Sildenafil (Massachusetts General Hospital) Schizophrenia Phase IV NCT00455715
Tadalafil (Västra Götaland Region) Diabetes Phase II NCT01238224
Tadalafil (University of Roma La Sapienza) Diabetic cardiomyopathy Phase IV NCT01803828
Tadalafil (Cedars-Sinai Medical Center) Becker muscular dystrophy Phase IV NCT01070511
Tadalafil (Sidney Kimmel Comprehensive Cancer
Center)
Multiple myeloma Phase II NCT01374217
Tadalafil (Washington University School of Medicine) Aortic stenosis Phase IV NCT01275339
Tadalafil (Sidney Kimmel Comprehensive Cancer
Center)
Head and neck cancer Phase IV NCT01697800
Tadalafil (Sanjay Gandhi Institute of Medical Sciences) Lung diseases Phase III NCT01553981
Udenafil (Seoul National University Hospital) Raynaud’s phenomenon Phase III NCT01280266
PF-00489791 (Pfizer) Diabetic nephropathy Phase III NCT01200394
PF-04447943 (Pfizer) Alzheimer’s disease Phase II NCT00930059
PF-04447943 (Pfizer) Alzheimer’s disease Phase II NCT00988598
PF-02545920 (Pfizer) Schizophrenia Phase I NCT01244880
PF-02545920 (Pfizer) Huntington’s disease Phase I NCT01806896
RO5545965 (Hoffmann-La Roche) Unknown Phase I NCT01923025
AMG 579 (Amgen) Schizophrenia Phase I NCT01568203
TAK- 063 (Takeda) Schizophrenia Phase I NCT01879722
AN2898 and AN2728 (Anacor Pharmaceuticals) Atopic dermatitis Phase II NCT01301508
COPD, chronic obstructive pulmonary disease; IRCCS, L’Istituto di Ricovero e Cura a Carattere Scientifico; PDE, phosphodiesterase.
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